Adamis Pharmaceuticals Corporation announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with high levels of the Omicron variant of the SARS-CoV-2 virus resulted in significant decrease of inflammation in the lungs of animals treated with Tempol compared to controls.